Q-omics provides the consensus-scored SPHKAP profile across patient tissues and cancer cell-line models. SPHKAP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPHKAP is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SPHKAP RNA expression shows 9,016 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where SPHKAP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPHKAP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPHKAP survival associations across molecular data types. SPHKAP RNA expression shows survival associations in the most cancer types (25), followed by mutation status (14) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPHKAP RNA expression–survival associations across cancer types. High SPHKAP expression shows unfavorable associations in KIRC, LIHC, BLCA, THCA and KICH, but favorable associations in LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for SPHKAP RNA expression.
This table summarizes SPHKAP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SPHKAP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPHKAP shows lower tumor expression in COAD, KIRC, THCA, KIRP, BRCA and BLCA. The COAD box plot shows higher SPHKAP RNA expression in normal versus tumor tissue (log2 FC = −0.132, t-test p < 0.001).
This table shows molecular features associated with SPHKAP in patient tissues and cancer cell lines. In patient samples, SPHKAP shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPHKAP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
